Text Size

Hematotoxic Effects of Particulate Exposure

This study has been completed.
Sponsor:
Information provided by:
National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov Identifier:
NCT00015483
First received: April 20, 2001
Last updated: September 1, 2006
Last verified: September 2006
History of Changes
  Purpose

Hematotoxicity is caused by a number of agents such as a benzene by-product called hydroquinone and the antitumor agent doxorubicin. This is a basic research study, conducted using normal human donors, of mechanisms involved in hematotoxicity and of the protective response of human hematopoietic progenitor cells to hematotoxic agents. Tumor necrosis factor exposure protects these cells from a subsequent exposure to hematotoxic agents. The alteration of gene expression in these cells caused by tumor necrosis factor is being studied. Additionally, the tumor necrosis factor-induced biochemical pathways involved in protection of human hematopoietic progenitor cells will be studied.


Condition
Cancer

Study Type: Observational
Study Design: Allocation: Random Sample
Official Title: Hematotoxic Effects of Benzene and Doxorubicin

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by National Institute of Environmental Health Sciences (NIEHS):

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • healthy
  • nonsmoking
  • no history of hematologic disorder
  • not pregnant
  • no medications which suppress hematopoiesis
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015483     History of Changes
Other Study ID Numbers: 5020-CP-001
Study First Received: April 20, 2001
Last Updated: September 1, 2006
Health Authority: United States: Federal Government

Keywords provided by National Institute of Environmental Health Sciences (NIEHS):
Hematotoxicity
Benzene
Bone Marrow

ClinicalTrials.gov processed this record on June 18, 2013